Minireviews
Copyright ©The Author(s) 2022.
World J Clin Oncol. Jan 24, 2022; 13(1): 39-48
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.39
Table 2 Retrospective studies published within the last decade investigating the impact of locoregional treatment to the primary tumor site in de novo metastatic breast cancer
Ref.
n
Treatment
Patient
Median follow-up (mo)
Outcomes
Ma et al[35]987Surgery (n = 463)Surgery arm: More T1-2, HR-positive, solitary metastasis, bone only metastasisNRMedian survival (mo): 45 vs 28, P < 0.001
No surgery (n = 524)
Better survival in surgery after systemic therapy than primary surgery
Triple negative, brain metastases: No benefit of surgery
Lane et al[16] (NCDB)24015Systemic therapy alone (n = 13505)Surgery after systemic therapy arm: Younger, more T3-4 and HR-negativeNRMedian OS (mo): 37.5 vs 49.4 vs 52.8, P < 0.001
Surgery before systemic therapy (n = 4552)RT: No impact on OS
Systemic therapy before surgery (n = 5958)
Li et al[36] (SEER database) 20870Surgery (n = 5779) Surgery arm: Younger, more T1-3, N+, Gr III, and less HR+NRSurgery arm (± RT): Improved BCSS and OS (P < 0.001)
No surgery (n = 15091)
More chemo and RT received
Pons-Tostivint et al[37]4276LRT (n = 1706): Surgery, RT or bothLRT arm: Younger, more solitary or bone-only metastases45.3Median OS (mo): HR-positive, HER2- negative: 61.6 vs 45.9, P < 0.001
No LRT (n = 2570)HR-positive, HER2-positive: 77.2 vs 52.6, P = 0.008
Triple negative: 19 vs 18.6, P = 0.54
Bone only metastases: 70.4 vs 62, P < 0.001
Visceral metastases: 83 vs 52.7, P < 0.001
Choi et al[38]245LRT (n = 82): Surgery, RT or both LRT arm: < T4, no liver or brain metastasis, and < 5 metastatic sites405-yr LRFS: 62% vs 20%, P < 0.001
5-yr OS:73% vs 45%, P = 0.02
No LRT (n = 163)
Gultekin et al[7]227LRT (n = 188): Surgery, RT or bothLRT arm: Less T3-4 and more solitary metastases355-yr OS: 56% vs 24%, P < 0.001
5-yr PFS: 27% vs 7%, P < 0.0001
No LRT (n = 39)
Nguyen et al[39]733LRT (n = 378): Surgery, RT or bothLRT arm: Younger, more T1-2, N0-1, limited M1 disease215-yr OS: 21% vs 14%, P < 0.001
5-yr PFS 72% vs 46%, P < 0.001
No LRT (n = 355)
Neuman et al[25]186Surgery (n = 69): 13% RTSurgery arm: More HER2-negative, smaller tumors, more solitary metastasis52No difference in OS (P = 0.10)
No surgery (n = 117)